Medicine
Amtagvi 72000000000/500 mL injectable suspension
Amtagvi 72000000000/500 mL injectable suspension is a prescription medicine containing Lifileucel for intravenous use, marketed by Iovance Biotherapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store AMTAGVI frozen in the vapor phase of liquid nitrogen (less than or equal…
Key facts
- Active ingredient (INN)
- Lifileucel
- Brand
- Amtagvi
- Strength
- 72000000000/500 mL
- Dosage form
- Injectable suspension
- Route
- Intravenous
- Packs
- 1 bag
- Marketing authorisation holder
- Iovance Biotherapeutics
- Manufacturer
- Iovance Biotherapeutics
- Origin register
- US FDA, United States
- Storage
- Store AMTAGVI frozen in the vapor phase of liquid nitrogen (less than or equal to minus 150°C).
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XL11 Lifileucel
- HS code (indicative)
- 3002.51Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 16 February 2024
- Identifiers
- RxCUI 2675868, 2675874DailyMed set ID 4121bd3f-2d6e-3bdd-e063-6294a90a3088NDC 73776-001Application BLA125773
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bag in 1 cartridge / 125 mL in 1 bag | 73776-001-12 | Iovance Biotherapeutics | 16 February 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Lifileucel is a prescription medicine indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, among other approved uses. MedsAcross supplies Lifileucel for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LifileucelFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- AMTAGVI prescribing information (Iovance Biotherapeutics) · U.S. National Library of Medicine, DailyMed
Need Amtagvi 72000000000/500 mL injectable suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.